COMP <GO>
PTCT vs JNJ // 10Y YIELD & FRED MACRO BETA
PTC Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PTCT 9
— JNJ 3
▲ 10Y YIELD & FRED MACRO BETA LEADER: PTCT
LAST: $64.46 (+2.29%) • MKT CAP: $5.38B
macro-sensitivity
1.15
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTCT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 25.50% | +59.50 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.5x | 18.5x | -12.00 | PTCT | /valuation <GO> |
| Free Cash Flow Yield | 13.05% | 2.97% | +10.08 | PTCT | /fcf-yield <GO> |
| Operating Margin | 50.10% | 34.70% | +15.40 | PTCT | /operating-margins <GO> |
| Net Profit Margin | 39.50% | 28.50% | +11.00 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 114.50% | 6.00% | +108.50 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.73 | 5.59 | -3.86 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 62.1 | -9.10 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.15 | 1.08 | +0.07 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.6x | 23.0x | -16.40 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $662.49B | -$657.11B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTCT REV | JNJ REV | PTCT GROSS % | JNJ GROSS % | PTCT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | $94.19B | — | 67.9% | $702.3M | $19.70B |
| FY 2024 | $806.8M | $88.82B | — | 69.1% | -$114.2M | $19.84B |
| FY 2023 | $937.8M | $85.16B | — | — | -$200.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
JNJ // BETA 1.08